- Home
- HKD vs STOK Comparison
HKD vs STOK Comparison
Compare HKD & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKD
- STOK
- Stock Information
- Founded
- HKD 2003
- STOK 2014
- Country
- HKD France
- STOK United States
- Employees
- HKD N/A
- STOK N/A
- Industry
- HKD Finance: Consumer Services
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- HKD Finance
- STOK Health Care
- Exchange
- HKD Nasdaq
- STOK Nasdaq
- Market Cap
- HKD 656.8M
- STOK 638.8M
- IPO Year
- HKD 2022
- STOK 2019
- Fundamental
- Price
- HKD $1.78
- STOK $11.48
- Analyst Decision
- HKD
- STOK Strong Buy
- Analyst Count
- HKD 0
- STOK 5
- Target Price
- HKD N/A
- STOK $24.50
- AVG Volume (30 Days)
- HKD 430.8K
- STOK 530.1K
- Earning Date
- HKD 01-01-0001
- STOK 08-06-2025
- Dividend Yield
- HKD N/A
- STOK N/A
- EPS Growth
- HKD 9.93
- STOK N/A
- EPS
- HKD 0.23
- STOK 0.88
- Revenue
- HKD $20,445,000.00
- STOK $190,908,000.00
- Revenue This Year
- HKD N/A
- STOK $378.84
- Revenue Next Year
- HKD N/A
- STOK N/A
- P/E Ratio
- HKD $7.73
- STOK $13.09
- Revenue Growth
- HKD N/A
- STOK 2333.81
- 52 Week Low
- HKD $1.65
- STOK $5.35
- 52 Week High
- HKD $5.80
- STOK $16.15
- Technical
- Relative Strength Index (RSI)
- HKD 44.03
- STOK 58.05
- Support Level
- HKD $1.70
- STOK $11.19
- Resistance Level
- HKD $1.85
- STOK $12.00
- Average True Range (ATR)
- HKD 0.08
- STOK 0.53
- MACD
- HKD 0.01
- STOK -0.10
- Stochastic Oscillator
- HKD 40.91
- STOK 28.70
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.